NCT04533737 - Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab | Biotech Hunter

Enrollment

113

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

September 8, 2022

Study Completion Date

December 7, 2022

Conditions

Plaque PsoriasisPsoriasis VulgarisPsoriasis

Interventions

BIOLOGICAL

Brodalumab

Pre-filled syringe with 210 mg brodalumab in 1.5 ml solution for subcutaneous injection

OTHER

Placebo

The placebo solution is similar to the active guselkumab (Dummy 1) or brodalumab (Dummy 2) solution except that it does not contain any active substance

BIOLOGICAL

Guselkumab

Pre-filled syringe with 100 mg guselkumab in 1 ml solution for subcutaneous injection

Trial Locations (65)

1090

LEO Pharma Investigational Site, Vienna

1200

LEO Pharma Investigational Site, Brussels

1311

LEO Pharma Investigational Site, Almere Stad

2400

LEO Pharma Investigational Site, Copenhagen

2900

LEO Pharma Investigational Site, Hellerup

4000

LEO Pharma Investigational Site, Roskilde

4040

LEO Pharma Investigational Site, Herstal

5000

LEO Pharma Investigational Site, Namur

8036

LEO Pharma Investigational Site, Graz

8091

LEO Pharma Investigational Site, Zurich

9007

LEO Pharma Investigational Site, Sankt Gallen

13008

LEO Pharma Investigational Site, Marseille

13500

LEO Pharma Investigational Site, Martigues

16121

LEO Pharma Investigational Site 1, Athens

LEO Pharma Investigational Site 2, Athens

18016

LEO Pharma Investigational Site, Granada

20089

LEO Pharma Investigational Site, Rozzano

20246

LEO Pharma Investigational Site, Hamburg

20537

LEO Pharma Investigational Site, Hamburg

21614

LEO Pharma Investigational Site, Buxtehude

24105

LEO Pharma Investigational Site, Kiel

28031

LEO Pharma Investigational Site, Madrid

28041

LEO Pharma Investigational Site, Madrid

31059

LEO Pharma Investigational Site, Toulouse

33611

LEO Pharma Investigational Site, Mieres

36001

LEO Pharma Investigational Site, Pontevedra

42277

LEO Pharma Investigational Site, Saint-Priest-en-Jarez

46026

LEO Pharma Investigational Site, Valencia

48013

LEO Pharma Investigational Site, Bilbao

48149

LEO Pharma Investigational Site, Münster

48455

LEO Pharma Investigational Site, Bad Bentheim

49565

LEO Pharma Investigational Site, Bramsche

50937

LEO Pharma Investigational Site, Cologne

52074

LEO Pharma Investigational Site, Aachen

53127

LEO Pharma Investigational Site, Bonn

54643

LEO Pharma Investigational Site 1, Thessaloniki

LEO Pharma Investigational Site 2, Thessaloniki

LEO Pharma Investigational Site, Thessaloniki

55128

LEO Pharma Investigational Site, Mainz

55131

LEO Pharma Investigational Site, Mainz

56126

LEO Pharma Investigational Site, Pisa

56242

LEO Pharma Investigational Site, Selters

60590

LEO Pharma Investigational Site, Frankfurt am Main

64297

LEO Pharma Investigational Site, Darmstadt

76031

LEO Pharma Investigational Site, Rouen

79104

LEO Pharma Investigational Site, Freiburg im Breisgau

80121

LEO Pharma Investigational Site, Napoli

80802

LEO Pharma Investigational Site, Munich

86163

LEO Pharma Investigational Site, Augsburg

87700

LEO Pharma Investigational Site, Memmingen

91054

LEO Pharma Investigational Site, Erlangen

92160

LEO Pharma Investigational Site, Antony

94160

LEO Pharma Investigational Site, Saint-Mandé

06000

LEO Pharma Investigational Site, Nice

00133

LEO Pharma Investigational Site, Roma

4614 VT

LEO Pharma Investigational Site, Bergen op Zoom

1105 AZ

LEO Pharma Investigational Site, Amsterdam

03010

LEO Pharma Investigational Site, Alicante

08036

LEO Pharma Investigational Site, Barcelona

08041

LEO Pharma Investigational Site, Barcelona

171 76

LEO Pharma Investigational Site, Solna

BA1 3NG

LEO Pharma Investigational Site, Bath

DY1 2HQ

LEO Pharma Investigational Site, Dudley

LS7 4SA

LEO Pharma investigational site, Leeds

SW17 0RE

LEO Pharma Investigational Site, London